> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biomedical Industry Seeks Senate Help on FDA Cuts
- URL: https://www.fdaweb.com/biomedical-industry-seeks-senate-help-on-fda-cuts/
- Published: 2025-04-10T12:00:00.000Z
- Updated: 2026-09-14T14:57:31.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158990

Hundreds of U.S. biomedical innovators and investors are urging the Senate to help restore critical FDA staff that were recently laid off so that institutional knowledge at the agency is not lost. In a 4/6 [letter](https://www.nopatientleftbehind.org/preserving-the-fda?ref=fdaweb.com) to senator **Bill Cassidy** (R-LA), the stakeholders say that having an “adequately staffed” FDA is “particularly essential for small, clinical-stage biotechs that are typically resource constrained and rely on investor capital to meet the FDA’s requirements and standards. Any delays in FDA reviews will substantially impact these companies’ ability to secure the funding they need to continue to advance to the next stage of development.”

The letter seeks Cassidy’s help in encouraging the Trump administration to re-hire key people who carry substantial institutional knowledge and lift FDA’s hiring freeze to ensure all key roles are adequately staffed to ensure clarity and consistency. “Inconsistent feedback during development leads to delays, waste, and an immeasurable human cost,” the letter says. “A culture of rigorously following the science and clearly communicating important information about product safety, regulatory guidance, policy, and FDA-decision making is crucial. The FDA should continue to participate in ongoing dialogues with patient groups, academics, other global regulators, and industry to pursue needed regulatory reforms that align with US goals. Communication is therefore a core function.”

Additionally, staff cuts have disrupted the Prescription Drug User Fee Act and jeopardizes the future of the program, the letter says. “Negotiating PDUFA reauthorization and determining staffing requirements to meet the agency’s stated goals is crucial to ensuring timely reviews for medicines,” according to the stakeholders. “It is the industry’s goal to continue to help fund the FDA and yet we worry that lapses at the FDA might result in the FDA not being allowed to collect fees or even renegotiate a way for industry to keep paying fees. Please protect the FDA’s ability to continue to collect user fees.”